0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global LV-Based Cell and Gene Therapy Products Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-0D17310
Home | Market Reports | Science| Biological Sciences
Global LV Based Cell and Gene Therapy Products Market Research Report 2024
BUY CHAPTERS

Global LV-Based Cell and Gene Therapy Products Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-0D17310
Report
November 2025
Pages:121
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

LV-Based Cell and Gene Therapy Products Market

The global LV-Based Cell and Gene Therapy Products market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
LV-based cell and gene therapy products refer to therapeutic products that utilize lentiviral vectors (LV) as a delivery system for introducing genetic material into target cells. Lentiviral vectors are commonly used in gene therapy to transfer genes into cells for the treatment of genetic disorders, cancer, and other diseases.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
LV-Based Cell and Gene Therapy Products leading manufacturers including Novartis, Bluebird Bio, Thermo Fisher Scientific, Intas, BMS, Orchard Therapeutics, etc., dominate supply; the top five capture approximately % of global revenue, with Novartis leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global LV-Based Cell and Gene Therapy Products market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of LV-Based Cell and Gene Therapy Products Market Report

Report Metric Details
Report Name LV-Based Cell and Gene Therapy Products Market
Segment by Type
  • CAR-T Therapy
  • Autologous CD34+ Cell Gene Therapy
Segment by Application
  • Hospital
  • Diagnostic and Testing Laboratories
  • Academic and Research Organizations
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Novartis, Bluebird Bio, Thermo Fisher Scientific, Intas, BMS, Orchard Therapeutics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the LV-Based Cell and Gene Therapy Products study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the LV-Based Cell and Gene Therapy Products Market report?

Ans: The main players in the LV-Based Cell and Gene Therapy Products Market are Novartis, Bluebird Bio, Thermo Fisher Scientific, Intas, BMS, Orchard Therapeutics

What are the Application segmentation covered in the LV-Based Cell and Gene Therapy Products Market report?

Ans: The Applications covered in the LV-Based Cell and Gene Therapy Products Market report are Hospital, Diagnostic and Testing Laboratories, Academic and Research Organizations, Others

What are the Type segmentation covered in the LV-Based Cell and Gene Therapy Products Market report?

Ans: The Types covered in the LV-Based Cell and Gene Therapy Products Market report are CAR-T Therapy, Autologous CD34+ Cell Gene Therapy

1 Study Coverage
1.1 Introduction to LV-Based Cell and Gene Therapy Products: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global LV-Based Cell and Gene Therapy Products Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 CAR-T Therapy
1.2.3 Autologous CD34+ Cell Gene Therapy
1.3 Market Segmentation by Application
1.3.1 Global LV-Based Cell and Gene Therapy Products Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Diagnostic and Testing Laboratories
1.3.4 Academic and Research Organizations
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global LV-Based Cell and Gene Therapy Products Revenue Estimates and Forecasts 2020-2031
2.2 Global LV-Based Cell and Gene Therapy Products Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global LV-Based Cell and Gene Therapy Products Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global LV-Based Cell and Gene Therapy Products Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 CAR-T Therapy Market Size by Players
3.3.2 Autologous CD34+ Cell Gene Therapy Market Size by Players
3.4 Global LV-Based Cell and Gene Therapy Products Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global LV-Based Cell and Gene Therapy Products Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global LV-Based Cell and Gene Therapy Products Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America LV-Based Cell and Gene Therapy Products Market Size by Type (2020-2031)
6.4 North America LV-Based Cell and Gene Therapy Products Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America LV-Based Cell and Gene Therapy Products Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe LV-Based Cell and Gene Therapy Products Market Size by Type (2020-2031)
7.4 Europe LV-Based Cell and Gene Therapy Products Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe LV-Based Cell and Gene Therapy Products Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific LV-Based Cell and Gene Therapy Products Market Size by Type (2020-2031)
8.4 Asia-Pacific LV-Based Cell and Gene Therapy Products Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific LV-Based Cell and Gene Therapy Products Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America LV-Based Cell and Gene Therapy Products Market Size by Type (2020-2031)
9.4 Central and South America LV-Based Cell and Gene Therapy Products Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America LV-Based Cell and Gene Therapy Products Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa LV-Based Cell and Gene Therapy Products Market Size by Type (2020-2031)
10.4 Middle East and Africa LV-Based Cell and Gene Therapy Products Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa LV-Based Cell and Gene Therapy Products Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Business Overview
11.1.3 Novartis LV-Based Cell and Gene Therapy Products Product Features and Attributes
11.1.4 Novartis LV-Based Cell and Gene Therapy Products Revenue and Gross Margin (2020-2025)
11.1.5 Novartis LV-Based Cell and Gene Therapy Products Revenue by Product in 2024
11.1.6 Novartis LV-Based Cell and Gene Therapy Products Revenue by Application in 2024
11.1.7 Novartis LV-Based Cell and Gene Therapy Products Revenue by Geographic Area in 2024
11.1.8 Novartis LV-Based Cell and Gene Therapy Products SWOT Analysis
11.1.9 Novartis Recent Developments
11.2 Bluebird Bio
11.2.1 Bluebird Bio Corporation Information
11.2.2 Bluebird Bio Business Overview
11.2.3 Bluebird Bio LV-Based Cell and Gene Therapy Products Product Features and Attributes
11.2.4 Bluebird Bio LV-Based Cell and Gene Therapy Products Revenue and Gross Margin (2020-2025)
11.2.5 Bluebird Bio LV-Based Cell and Gene Therapy Products Revenue by Product in 2024
11.2.6 Bluebird Bio LV-Based Cell and Gene Therapy Products Revenue by Application in 2024
11.2.7 Bluebird Bio LV-Based Cell and Gene Therapy Products Revenue by Geographic Area in 2024
11.2.8 Bluebird Bio LV-Based Cell and Gene Therapy Products SWOT Analysis
11.2.9 Bluebird Bio Recent Developments
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Corporation Information
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific LV-Based Cell and Gene Therapy Products Product Features and Attributes
11.3.4 Thermo Fisher Scientific LV-Based Cell and Gene Therapy Products Revenue and Gross Margin (2020-2025)
11.3.5 Thermo Fisher Scientific LV-Based Cell and Gene Therapy Products Revenue by Product in 2024
11.3.6 Thermo Fisher Scientific LV-Based Cell and Gene Therapy Products Revenue by Application in 2024
11.3.7 Thermo Fisher Scientific LV-Based Cell and Gene Therapy Products Revenue by Geographic Area in 2024
11.3.8 Thermo Fisher Scientific LV-Based Cell and Gene Therapy Products SWOT Analysis
11.3.9 Thermo Fisher Scientific Recent Developments
11.4 Intas
11.4.1 Intas Corporation Information
11.4.2 Intas Business Overview
11.4.3 Intas LV-Based Cell and Gene Therapy Products Product Features and Attributes
11.4.4 Intas LV-Based Cell and Gene Therapy Products Revenue and Gross Margin (2020-2025)
11.4.5 Intas LV-Based Cell and Gene Therapy Products Revenue by Product in 2024
11.4.6 Intas LV-Based Cell and Gene Therapy Products Revenue by Application in 2024
11.4.7 Intas LV-Based Cell and Gene Therapy Products Revenue by Geographic Area in 2024
11.4.8 Intas LV-Based Cell and Gene Therapy Products SWOT Analysis
11.4.9 Intas Recent Developments
11.5 BMS
11.5.1 BMS Corporation Information
11.5.2 BMS Business Overview
11.5.3 BMS LV-Based Cell and Gene Therapy Products Product Features and Attributes
11.5.4 BMS LV-Based Cell and Gene Therapy Products Revenue and Gross Margin (2020-2025)
11.5.5 BMS LV-Based Cell and Gene Therapy Products Revenue by Product in 2024
11.5.6 BMS LV-Based Cell and Gene Therapy Products Revenue by Application in 2024
11.5.7 BMS LV-Based Cell and Gene Therapy Products Revenue by Geographic Area in 2024
11.5.8 BMS LV-Based Cell and Gene Therapy Products SWOT Analysis
11.5.9 BMS Recent Developments
11.6 Orchard Therapeutics
11.6.1 Orchard Therapeutics Corporation Information
11.6.2 Orchard Therapeutics Business Overview
11.6.3 Orchard Therapeutics LV-Based Cell and Gene Therapy Products Product Features and Attributes
11.6.4 Orchard Therapeutics LV-Based Cell and Gene Therapy Products Revenue and Gross Margin (2020-2025)
11.6.5 Orchard Therapeutics Recent Developments
12 LV-Based Cell and Gene Therapy ProductsIndustry Chain Analysis
12.1 LV-Based Cell and Gene Therapy Products Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 LV-Based Cell and Gene Therapy Products Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global LV-Based Cell and Gene Therapy Products Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
 Table 1. Global LV-Based Cell and Gene Therapy Products Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global LV-Based Cell and Gene Therapy Products Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global LV-Based Cell and Gene Therapy Products Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global LV-Based Cell and Gene Therapy Products Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global LV-Based Cell and Gene Therapy Products Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global LV-Based Cell and Gene Therapy Products Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global LV-Based Cell and Gene Therapy Products Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global LV-Based Cell and Gene Therapy Products by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in LV-Based Cell and Gene Therapy Products as of 2024)
 Table 11. Global LV-Based Cell and Gene Therapy Products Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global LV-Based Cell and Gene Therapy Products Companies Headquarters
 Table 13. Global LV-Based Cell and Gene Therapy Products Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global LV-Based Cell and Gene Therapy Products Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global LV-Based Cell and Gene Therapy Products Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global LV-Based Cell and Gene Therapy Products Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global LV-Based Cell and Gene Therapy Products Revenue by Application (2026-2031) & (US$ Million)
 Table 21. LV-Based Cell and Gene Therapy Products High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America LV-Based Cell and Gene Therapy Products Growth Accelerators and Market Barriers
 Table 25. North America LV-Based Cell and Gene Therapy Products Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe LV-Based Cell and Gene Therapy Products Growth Accelerators and Market Barriers
 Table 27. Europe LV-Based Cell and Gene Therapy Products Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific LV-Based Cell and Gene Therapy Products Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific LV-Based Cell and Gene Therapy Products Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America LV-Based Cell and Gene Therapy Products Investment Opportunities and Key Challenges
 Table 31. Central and South America LV-Based Cell and Gene Therapy Products Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa LV-Based Cell and Gene Therapy Products Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa LV-Based Cell and Gene Therapy Products Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Novartis Corporation Information
 Table 35. Novartis Description and Major Businesses
 Table 36. Novartis Product Features and Attributes
 Table 37. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Novartis Revenue Proportion by Product in 2024
 Table 39. Novartis Revenue Proportion by Application in 2024
 Table 40. Novartis Revenue Proportion by Geographic Area in 2024
 Table 41. Novartis LV-Based Cell and Gene Therapy Products SWOT Analysis
 Table 42. Novartis Recent Developments
 Table 43. Bluebird Bio Corporation Information
 Table 44. Bluebird Bio Description and Major Businesses
 Table 45. Bluebird Bio Product Features and Attributes
 Table 46. Bluebird Bio Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Bluebird Bio Revenue Proportion by Product in 2024
 Table 48. Bluebird Bio Revenue Proportion by Application in 2024
 Table 49. Bluebird Bio Revenue Proportion by Geographic Area in 2024
 Table 50. Bluebird Bio LV-Based Cell and Gene Therapy Products SWOT Analysis
 Table 51. Bluebird Bio Recent Developments
 Table 52. Thermo Fisher Scientific Corporation Information
 Table 53. Thermo Fisher Scientific Description and Major Businesses
 Table 54. Thermo Fisher Scientific Product Features and Attributes
 Table 55. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Thermo Fisher Scientific Revenue Proportion by Product in 2024
 Table 57. Thermo Fisher Scientific Revenue Proportion by Application in 2024
 Table 58. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2024
 Table 59. Thermo Fisher Scientific LV-Based Cell and Gene Therapy Products SWOT Analysis
 Table 60. Thermo Fisher Scientific Recent Developments
 Table 61. Intas Corporation Information
 Table 62. Intas Description and Major Businesses
 Table 63. Intas Product Features and Attributes
 Table 64. Intas Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Intas Revenue Proportion by Product in 2024
 Table 66. Intas Revenue Proportion by Application in 2024
 Table 67. Intas Revenue Proportion by Geographic Area in 2024
 Table 68. Intas LV-Based Cell and Gene Therapy Products SWOT Analysis
 Table 69. Intas Recent Developments
 Table 70. BMS Corporation Information
 Table 71. BMS Description and Major Businesses
 Table 72. BMS Product Features and Attributes
 Table 73. BMS Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. BMS Revenue Proportion by Product in 2024
 Table 75. BMS Revenue Proportion by Application in 2024
 Table 76. BMS Revenue Proportion by Geographic Area in 2024
 Table 77. BMS LV-Based Cell and Gene Therapy Products SWOT Analysis
 Table 78. BMS Recent Developments
 Table 79. Orchard Therapeutics Corporation Information
 Table 80. Orchard Therapeutics Description and Major Businesses
 Table 81. Orchard Therapeutics Product Features and Attributes
 Table 82. Orchard Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Orchard Therapeutics Recent Developments
 Table 84. Raw Materials Key Suppliers
 Table 85. Distributors List
 Table 86. Market Trends and Market Evolution
 Table 87. Market Drivers and Opportunities
 Table 88. Market Challenges, Risks, and Restraints
 Table 89. Research Programs/Design for This Report
 Table 90. Key Data Information from Secondary Sources
 Table 91. Key Data Information from Primary Sources


List of Figures
 Figure 1. LV-Based Cell and Gene Therapy Products Product Picture
 Figure 2. Global LV-Based Cell and Gene Therapy Products Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. CAR-T Therapy Product Picture
 Figure 4. Autologous CD34+ Cell Gene Therapy Product Picture
 Figure 5. Global LV-Based Cell and Gene Therapy Products Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Hospital
 Figure 7. Diagnostic and Testing Laboratories
 Figure 8. Academic and Research Organizations
 Figure 9. Others
 Figure 10. LV-Based Cell and Gene Therapy Products Report Years Considered
 Figure 11. Global LV-Based Cell and Gene Therapy Products Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 13. Global LV-Based Cell and Gene Therapy Products Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global LV-Based Cell and Gene Therapy Products Revenue Market Share by Region (2020-2031)
 Figure 15. Global LV-Based Cell and Gene Therapy Products Revenue Market Share Ranking (2024)
 Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 17. CAR-T Therapy Revenue Market Share by Player in 2024
 Figure 18. Autologous CD34+ Cell Gene Therapy Revenue Market Share by Player in 2024
 Figure 19. Global LV-Based Cell and Gene Therapy Products Revenue Market Share by Type (2020-2031)
 Figure 20. Global LV-Based Cell and Gene Therapy Products Revenue Market Share by Application (2020-2031)
 Figure 21. North America LV-Based Cell and Gene Therapy Products Revenue YoY (2020-2031) & (US$ Million)
 Figure 22. North America Top 5 Players LV-Based Cell and Gene Therapy Products Revenue (US$ Million) in 2024
 Figure 23. North America LV-Based Cell and Gene Therapy Products Revenue (US$ Million) by Type (2020 - 2031)
 Figure 24. North America LV-Based Cell and Gene Therapy Products Revenue (US$ Million) by Application (2020-2031)
 Figure 25. US LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 26. Canada LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 27. Mexico LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 28. Europe LV-Based Cell and Gene Therapy Products Revenue YoY (2020-2031) & (US$ Million)
 Figure 29. Europe Top 5 Players LV-Based Cell and Gene Therapy Products Revenue (US$ Million) in 2024
 Figure 30. Europe LV-Based Cell and Gene Therapy Products Revenue (US$ Million) by Type (2020-2031)
 Figure 31. Europe LV-Based Cell and Gene Therapy Products Revenue (US$ Million) by Application (2020-2031)
 Figure 32. Germany LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 33. France LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 34. U.K. LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 35. Italy LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 36. Russia LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 37. Asia-Pacific LV-Based Cell and Gene Therapy Products Revenue YoY (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific Top 8 Players LV-Based Cell and Gene Therapy Products Revenue (US$ Million) in 2024
 Figure 39. Asia-Pacific LV-Based Cell and Gene Therapy Products Revenue (US$ Million) by Type (2020-2031)
 Figure 40. Asia-Pacific LV-Based Cell and Gene Therapy Products Revenue (US$ Million) by Application (2020-2031)
 Figure 41. Indonesia LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 42. Japan LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 43. South Korea LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 44. Australia LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 45. India LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 46. Indonesia LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 47. Vietnam LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 48. Malaysia LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 49. Philippines LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 50. Singapore LV-Based Cell and Gene Therapy Products Revenue (2020-2031) & (US$ Million)
 Figure 51. Central and South America LV-Based Cell and Gene Therapy Products Revenue YoY (2020-2031) & (US$ Million)
 Figure 52. Central and South America Top 5 Players LV-Based Cell and Gene Therapy Products Revenue (US$ Million) in 2024
 Figure 53. Central and South America LV-Based Cell and Gene Therapy Products Revenue (US$ Million) by Type (2020-2031)
 Figure 54. Central and South America LV-Based Cell and Gene Therapy Products Revenue (US$ Million) by Application (2020-2031)
 Figure 55. Brazil LV-Based Cell and Gene Therapy Products Revenue (2020-2025) & (US$ Million)
 Figure 56. Argentina LV-Based Cell and Gene Therapy Products Revenue (2020-2025) & (US$ Million)
 Figure 57. Middle East and Africa LV-Based Cell and Gene Therapy Products Revenue YoY (2020-2031) & (US$ Million)
 Figure 58. Middle East and Africa Top 5 Players LV-Based Cell and Gene Therapy Products Revenue (US$ Million) in 2024
 Figure 59. South America LV-Based Cell and Gene Therapy Products Revenue (US$ Million) by Type (2020-2031)
 Figure 60. Middle East and Africa LV-Based Cell and Gene Therapy Products Revenue (US$ Million) by Application (2020-2031)
 Figure 61. GCC Countries LV-Based Cell and Gene Therapy Products Revenue (2020-2025) & (US$ Million)
 Figure 62. Israel LV-Based Cell and Gene Therapy Products Revenue (2020-2025) & (US$ Million)
 Figure 63. Egypt LV-Based Cell and Gene Therapy Products Revenue (2020-2025) & (US$ Million)
 Figure 64. South Africa LV-Based Cell and Gene Therapy Products Revenue (2020-2025) & (US$ Million)
 Figure 65. LV-Based Cell and Gene Therapy Products Industry Chain Mapping
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS